INDP Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 9.28%, SMA50 -11.74%, SMA200 -61.99%). The stock’s 14-day RSI is 49.38 (neutral), while the ATR of 0.22 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -95.67% below its high and over 35.72% above its low. Average 10-day trading volume of 20.76 thousand shares is below the 3-month average of 166.06 thousand, indicating normal recent market interest.

Indaptus Therapeutics, Inc. generated EPS of -$31.51 over the past year. Five-year average earnings growth is 57.27%. Wall Street analysts project EPS growth of 53.89% annually over the next five years. The latest quarter delivered EPS of -$2.98. The next quarter is forecast at -$4.36. Next year's EPS is expected at $8.95. Indaptus Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 12, 2025, missed forecasts by -28.44%. The prior quarter beat by -1.62%. Over the last six quarters, Apple has recorded several small beats. These include -12.97% in August 12, 2024.

Indaptus Therapeutics, Inc. has 1.11 million shares outstanding. The public float is 889.33 thousand shares, elevated short interest at 1.17% of float. This equals 11.44 thousand shares. The short ratio is 0.49 days. Institutional investors hold 5.88% of the float. Insiders own 19.63%. Newman Michael James holds 1.37 million shares, Anderson Glen R. has 1.19 million shares and Meckler Jeffrey A has 75.37 thousand shares. Over the past six months, insider transactions show net selling. They sold 700.00 thousand shares across 1 transactions.

Indaptus Therapeutics, Inc. (NASDAQ:INDP) closed at $1.76 USD, gaining $0.06 (3.53%) from the previous close of $1.70. The stock is currently mid-range between its 52-week high and low $1.52 and $21.84. With a market capitalization of about $3.08 million, Indaptus Therapeutics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.00). Key stats such as the average daily volume over the past year has been around 648.74 thousand shares, volume is running light vs its 52-week average. Headquartered in New York City, NY, Indaptus Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David Elliot Lazar, the company employs approximately 7 people and listed since August 04, 2015. Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products.

Indaptus Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.61. This means the shares are trading above this model’s fair value.

Indaptus Therapeutics, Inc. trades at a P/E ratio of -0.18, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.2 suggesting the stock is closer to book value. The P/FCF stands at -0.2, also above market averages.

Indaptus Therapeutics, Inc. (NASDAQ:INDP) shares are flat -0.69% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Indaptus Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.18. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.60, suggesting 641.18% upside. Our AI forecast model points to short-term weakness (-0.59% over two weeks), a medium-term fall (-75.88% over three months), and a longer-term loss (-95.29% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Indaptus Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.59%, with price expected at $1.69 by April 07, 2026, within a range of $1.54 to $1.86 3-Month Outlook: Projected fall of -75.88%, reaching $0.41 by June 22, 2026, with a range of $0.00 to $0.97. 1-Year Outlook: Projected loss of -95.29%, with price at $0.08 by March 24, 2027, within a range of $0.00 to $1.23.